Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
He is also inducted as a member of the management council and senior management personnel of the company
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Launch innovative vitamin sublingual sprays
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Arco Lab now holds a 50% stake in Neviton
Subscribe To Our Newsletter & Stay Updated
